勃起不全:治療薬開発パイプライン分析

◆英語タイトル:Erectile Dysfunction - Pipeline Review, H1 2018
◆商品コード:GMDHC10104IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2018年1月23日
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥214,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥428,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥642,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界における勃起不全の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。
・イントロダクション
・勃起不全の概要
・勃起不全治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・勃起不全パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・企業別、開発中の製品
・大学/研究機関別、研究中の製品
・勃起不全治療薬開発に取り組んでいる企業:企業別製品パイプライン
・勃起不全治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Erectile Dysfunction – Pipeline Review, H1 2018

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Erectile Dysfunction – Pipeline Review, H1 2018, provides an overview of the Erectile Dysfunction (Male Health) pipeline landscape.

Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants, antihistamines and medications to treat high blood pressure, pain or prostate cancer.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Erectile Dysfunction – Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Erectile Dysfunction (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Erectile Dysfunction (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Erectile Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 4, 6, 3, 1, 13, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Erectile Dysfunction (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Erectile Dysfunction (Male Health).
- The pipeline guide reviews pipeline therapeutics for Erectile Dysfunction (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Erectile Dysfunction (Male Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Erectile Dysfunction (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Erectile Dysfunction (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Erectile Dysfunction (Male Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Erectile Dysfunction (Male Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Erectile Dysfunction – Overview
Erectile Dysfunction – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Erectile Dysfunction – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Erectile Dysfunction – Companies Involved in Therapeutics Development
Apricus Biosciences Inc
Aquestive Therapeutics
Astellas Pharma Inc
Biolab Farmaceutica Ltda
Biopharm GmbH
Biozeus
Can-Fite BioPharma Ltd
Fabre-Kramer Pharmaceuticals Inc
Futura Medical Plc
Hanmi Pharmaceuticals Co Ltd
Humanetics Corp
IntelGenx Corp
Ion Channel Innovations LLC
iX Biopharma Ltd
Mezzion Pharma Co Ltd
Mitsubishi Tanabe Pharma Corp
N4 Pharma Plc
NAL Pharmaceuticals Ltd
Nanoform Cardiovascular Therapeutics Ltd
Palatin Technologies Inc
Pharmicell Co Ltd
SK Chemicals Co Ltd
Suda Ltd
XuanZhu Pharma Co Ltd
Yangtze River Pharmaceutical Group
Yungjin Pharm Co Ltd
Erectile Dysfunction – Drug Profiles
alprostadil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AP-185 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avanafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BIO-300 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BL-214 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BZ-371 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cellgram-ED – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-602 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FKK-01PD – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HCP-1302 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPED-2015 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
libiguins – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2002 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MED-2005 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mirabegron ER – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pVAX-hSlo – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Bone Fracture, Degenerative Disc Disease, Erectile Dysfunction and Parkinson’s Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize CXCR4 for Erectile Dysfunction – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sildenafil citrate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit PDE5 for Erectile Dysfunction – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SUD-003 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
T-6932 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tadalafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TF-0092 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPN-729 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TR-399 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
udenafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XZP-5849 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YBH-1603 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Yonkenafil – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Erectile Dysfunction – Dormant Projects
Erectile Dysfunction – Discontinued Products
Erectile Dysfunction – Product Development Milestones
Featured News & Press Releases
Dec 15, 2017: Initiator Pharma reports positive results from the 28 days toxicology study in mini-pigs for its lead drug candidate IPED2015
Nov 22, 2017: Initiator Pharma receives positive result from the toxicology and toxicokinetic studies for its lead drug candidate IPED2015
Oct 31, 2017: Humanetics Presents Data on Potential Treatment to Prevent Erectile Dysfunction in Prostate Cancer Patients
Oct 26, 2017: Initiator Pharma initiates toxicology and toxicokinetic studies for its lead drug candidate IPED2015
Oct 10, 2017: Apricus Biosciences to Present at the 2017 BIO Investor Forum
Oct 10, 2017: N4 Pharma: Sildenafil PCT Update
Sep 07, 2017: A busy summer is providing valuable and Positive Results from the first Maximum tolerated dose toxicology for drug Candidate IPED2015
Aug 31, 2017: Apricus Biosciences Announces FDA Acknowledgement of Vitaros Class 2 NDA Resubmission
Aug 29, 2017: Apricus Biosciences Files NDA Resubmission for Vitaros
Aug 23, 2017: iX Biopharma Provides Update on PheoniX
Jul 27, 2017: N4 Pharma: Filing of Patents and Sildenafil Update
Jul 27, 2017: N4 Pharma: Update on Sildenafil clinical plans
May 11, 2017: iX Biopharma Files for the Registration of PheoniX (Sublingual Sildenafil)
May 09, 2017: Synthesis route for IPED2015 Selected
May 04, 2017: Apricus Biosciences Announces the Initiation of Vitaros Drug-Device Human Factors Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Erectile Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Products under Development by Universities/Institutes, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H1 2018
Erectile Dysfunction - Pipeline by Aquestive Therapeutics, H1 2018
Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H1 2018
Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H1 2018
Erectile Dysfunction - Pipeline by Biopharm GmbH, H1 2018
Erectile Dysfunction - Pipeline by Biozeus, H1 2018
Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H1 2018
Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H1 2018
Erectile Dysfunction - Pipeline by Futura Medical Plc, H1 2018
Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Humanetics Corp, H1 2018
Erectile Dysfunction - Pipeline by IntelGenx Corp, H1 2018
Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H1 2018
Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H1 2018
Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018
Erectile Dysfunction - Pipeline by N4 Pharma Plc, H1 2018
Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H1 2018
Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H1 2018
Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H1 2018
Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Suda Ltd, H1 2018
Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H1 2018
Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H1 2018
Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H1 2018
Erectile Dysfunction - Dormant Projects, H1 2018
Erectile Dysfunction - Dormant Projects, H1 2018 (Contd..1), H1 2018
Erectile Dysfunction - Dormant Projects, H1 2018 (Contd..2), H1 2018
Erectile Dysfunction - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Erectile Dysfunction, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products under Development by Universities/Institutes, H1 2018
Number of Products by Top 10 Targets, H1 2018
Number of Products by Stage and Top 10 Targets, H1 2018
Number of Products by Top 10 Mechanism of Actions, H1 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018
Number of Products by Top 10 Routes of Administration, H1 2018
Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

【レポートのキーワード】

勃起不全

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[勃起不全:治療薬開発パイプライン分析]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆